Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 15,646,085 shares of a nominal value of DKK 31,292,170, equivalent to 4.99% of Novozymes A/S’ share capital and 1.96% of the voting rights.
Major shareholder announcement
In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 4.99%, previously reported at 7.45% in company announcement no. 25, November 2013.
| Source: Novonesis (Novozymes A/S)
Attachments
Recommended Reading
-
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Read More -
COPENHAGEN, Denmark – May 5, 2026. In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%. Ester Baiget, President & CEO: ...
Read More